Affordable Access

deepdyve-link
Publisher Website

Pharmacokinetically-based prediction of the effects of antibiotic combinations on resistant Staphylococcus aureus mutants: in vitro model studies with linezolid and rifampicin.

Authors
  • Firsov, Alexander A1
  • Golikova, Maria V1
  • Strukova, Elena N1
  • Portnoy, Yury A1
  • Dovzhenko, Svetlana A1
  • Kobrin, Mikhail B1
  • Zinner, Stephen H2
  • 1 a Department of Pharmacokinetics & Pharmacodynamics , Gause Institute of New Antibiotics , Moscow 119021 , Russia.
  • 2 b Department of Medicine , Mount Auburn Hospital, Harvard Medical School , Cambridge , MA , USA.
Type
Published Article
Journal
Journal of chemotherapy (Florence, Italy)
Publication Date
Aug 01, 2017
Volume
29
Issue
4
Pages
220–226
Identifiers
DOI: 10.1080/1120009X.2016.1245174
PMID: 27748167
Source
Medline
Keywords
License
Unknown

Abstract

To explore if combinations of linezolid (L) with rifampicin (R) are able to restrict Staphylococcus aureus resistance, the enrichment of L- and R-resistant mutants was studied in an in vitro dynamic model. L- and R-resistant mutants were enriched in all single drug treatments. In contrast, L-resistant mutants were not enriched and R-resistant mutants were similar to baseline amounts with only minimal regrowth at the end of the combination treatments. These effects appear to be explained by lowering the mutant prevention concentration (MPC) for L+R combinations (MPCL+R) compared to the MPCs of L and R alone (MPCL and MPCR) and thereby the longer times above MPCL+R (73-100% of the dosing interval for L and 42-58% for R) compared to the times above MPCL (0-44%) and MPCR (0%). These findings provide an opportunity to predict the selection of S. aureus resistance in L+R treatments using MPCL+Rs.

Report this publication

Statistics

Seen <100 times